XA+ NHL is a fictional subtype of a real disease. All content shown here, including claims, data and references, is fictional and intended to represent a hypothetical clinical scenario.

About XA+ NHL

X-antigen-positive (XA+) non-Hodgkin’s lymphoma (NHL) is a particularly aggressive subtype of NHL, with a poor prognosis1

XA+ NHL is an aggressive subtype with rapid progression and a low survival rate.1

5-year survival rate

Symptoms are similar to other types of NHL; however, the XA+ subtype progresses quickly, so patients are likely to be diagnosed at a later stage.1

Current treatments do not effectively target malignant cells and therefore have high toxicity1

  • Unlike in other types of NHL, monoclonal antibody treatments show poor efficacy in XA+ subtypes and are generally not used.1
  • Chemotherapy is the standard of care, but has limited efficacy and high toxicity.1

1 in 4

XA+ NHL patients discontinue chemotherapy due to adverse events.1